Patric Nelson

发表

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

C. Schnabel, M. Fineman, X. Guan, 2007, Diabetes technology & therapeutics.

Modeling Dynamic Fluctuations in Type 1 Diabetes Progression: Quantifying β -cell variation after the appearance of islet-specific autoimmune responses

Stanca M. Ciupe, G. Omenn, W. Zou, 2015 .

Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes

D. Harlan, L. Spain, K. Rother, 2009, Diabetes Care.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Association Between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients With Type 1 Diabetes

R. Pop-Busui, Patric Nelson, Cynthia D Plunkett, 2014, Diabetes Care.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, JAMA.

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

Jennifer G. Robinson, Patric Nelson, S. Wasserman, 2014, Clinical cardiology.

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

R. Holman, C. Ballantyne, D. Blom, 2017, Diabetes, obesity & metabolism.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.

Kristin Taylor, Dennis D. Kim, M. Fineman, 2005, Diabetes technology & therapeutics.

Translating glucose variability metrics into the clinic via Continuous Glucose Monitoring: a Graphical User Interface for Diabetes Evaluation (CGM-GUIDE©).

Lo-Hua Yuan, Renata A Rawlings, Hang Shi, 2011, Diabetes technology & therapeutics.